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a b s t r a c t 
Tumor Protein 53-Induced Nuclear Protein 1 (TP53INP1) plays an important role during cell stress response
in synergy with the potent “genome-keeper” p53. In human, the gene encoding TP53INP1 is expressed at
very high level in some pathological situations, such as inﬂammation and prostate cancer (PC). TP53INP1
overexpression in PC seems to be a worse prognostic factor, particularly predictive of biological cancer
relapse, making TP53INP1 a relevant speciﬁc target for molecular therapy of Castration Resistant (CR) PC. In
that context, detection of TP53INP1 in patient biological ﬂuids is a promising diagnostic avenue. We report
here successful development of a new Enzyme-Linked Immunosorbent Assay (ELISA) detecting TP53INP1,
taking advantage of molecular tools (monoclonal antibodies (mAbs) and recombinant proteins) generated in
the laboratory during the course of basic functional investigations devoted to TP53INP1. The ELISA principle
is based on a sandwich immunoenzymatic system, TP53INP1 protein being trapped by a ﬁrst speciﬁc mAb
coated on microplate then recognized by a second speciﬁc mAb. This new assay allows speciﬁc detection of
TP53INP1 in serum of several PC patients. This breakthrough paves the way towards investigation of a large
cohort of patients and assessment of clinical applications of TP53INP1 dosage. 
c © 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license. 
 
 
 
 
 
 
 
 
 
 
 
 1. Introduction 
The protein p53 is the most famous tumor suppressor in the ﬁeld
of oncology for basic research scientists as well as clinicians. p53 is
highly induced upon stress events, and plays a crucial role in tumor
suppression by triggering growth arrest, senescence and apoptosis.
This protein is encoded by the TP53 gene which is mutated or lost
in a large range of human cancers [ 1 , 2 ]. Interestingly, in the case of
mutations giving rise to overexpression of mutated protein acting likeAbbreviations: aa, amino acid; CR PC, castration resistant prostate cancer; ELISA, 
enzyme-linked immunosorbent assay; HRP, horse radish peroxydase; SFM, serum free 
medium; TP53INP1, tumor protein 53-induced nuclear protein 1. 
* Correspondence to: INSERM U1068 / CRCM, Parc Scientiﬁque de Luminy, 163 Av- 
enue de Luminy, 13288 Marseille Cedex 9, France. Tel.: + 33 4 91 82 88 29; fax: + 33 
4 91 82 60 83. 
E-mail address: alice.carrier@inserm.fr (A. Carrier). 
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Open access under CC BY-NC-ND lican oncoprotein, p53 protein as well as auto-antibodies are detected
in the serum of patients [ 3 ]. 
The main activity of p53 is the modulation of gene expression
at the transcriptional level. One p53 transcriptional target is Tu-
mor Protein 53-Induced Nuclear Protein 1 (TP53INP1) that we have
characterized as a key stress factor dependently or not of p53 [ 4 –
9 ]. The TP53INP1 gene encodes two protein isoforms, TP53INP1 α
and TP53INP1 β (164 and 240 aminoacids in human, 163 and 239
aminoacids in mouse, respectively), resulting from alternative splic-
ing of the transcript [ 6 , 10 ]. These two isoforms are identical in se-
quence, except the additional C-terminal part in TP53INP1 β. They do
not show any known motif, apart from a sequence rich in proline, glu-
tamic acid, serine and threonine residues (PEST region characteristic
of short half-lives proteins) from aminoacid (aa) 26 to 62, and a LIR
(LC3-interacting region) from aa 25 to 37 which allows interaction
between TP53INP1 and LC3 within the autophagosomes [ 11 ]. To date,
any difference between the cellular effects of each isoform has been
identiﬁed. 
We developed monoclonal antibodies (mAbs) raised againstense.
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rP53INP1 α in order to recognize both isoforms (see above). The 
Ab E12 which is efﬁcient in immunohistochemistry on parafﬁn- 
mbedded organ sections was widely used by us and other labora- 
ories worldwide to assess expression of TP53INP1 in several human 
umor samples. Interestingly, these studies showed that TP53INP1 is 
ither lost or overexpressed in tumoral part of different organs ( Table 
 ). Those observations suggest that TP53INP1 has dual roles, with 
roperties of either a tumor suppressor or an oncoprotein. We gen- 
rated TP53INP1-deﬁcient mice and showed that they are prone to 
evelop tumors, consistent with a tumor suppressive function. This 
henotype is associated with increased levels of Reactive Oxygen 
pecies (ROS) and defective antioxidant defenses, suggesting an an- 
ioxidant role of TP53INP1 [ 12 –15 ]. At the cellular level, we showed 
hat TP53INP1 is involved in every one of the biological processes 
eregulated in cancer cells, in tight relation with its role in redox 
ontrol [ 11 , 12 , 14 –16 ]. 
By contrast with most cancers ( Table 1 ), TP53INP1 is over- 
xpressed in prostate cancer (PC). PC is one of the most common ma- 
ignancies in industrialized countries, and the second leading cause of 
ancer-related death in the United States. TP53INP1 overexpression 
n PC seems to be a worse prognostic factor, particularly predictive 
f biological cancer relapse [ 17 ]. Further works demonstrated that 
P53INP1 could be considered as a relevant speciﬁc target for molec- 
lar therapy of Castration Resistant (CR) PC [ 18 ]. In addition, TP53INP1 
ould be a new molecular marker that would help to deﬁne prostate 
ancer aggressiveness in diagnostic. TP53INP1 dosage could be done 
n parallel of PSA dosage, which is endowed with severe limitations, 
he most inconvenient one being that PSA may not be expressed in all 
ases of prostatic adenocarcinoma. Another limitation is that elevated 
SA is not only due to prostate cancer. A combination of dosages in- 
luding TP53INP1 dosage is a therapeutic avenue which would help to 
mprove PC patient diagnosis, prognosis and treatment. In that con- 
ext, evaluation of the clinical interest of TP53INP1 dosage not only by 
mmunochemistry but also in biological ﬂuids (serum and urine) of 
atients could contribute to this effort. Altogether, these innovative 
iagnostic and therapeutic avenues highlight the need to develop an 
ssay for detection of TP53INP1 in the serum of patients. 
In this paper, we report our successful endeavor to develop 
n Enzyme-Linked Immunosorbent Assay (ELISA) for detection of 
P53INP1. This ELISA takes advantage from tools for TP53INP1 studies 
enerated in the laboratory (monoclonal antibodies and recombinant 
roteins) as well as from established expertise in development [ 19 ] 
nd commercialization of clinically-relevant ELISA assays by Dynabio 
.A. 
. Materials and methods 
.1. Monoclonal antibodies speciﬁc of TP53INP1 
.1.1. Selection of hybridomas secreting monoclonal anti-TP53INP1 an- 
ibodies 
The selection procedure was described previously [ 12 ]. Hybridoma 
hat were found positive upon ELISA screening on TP53INP1 α-coated 
lates were further tested by Western blotting on recombinant 
P53INP1 produced in a bacterial expression system. Then the isotype 
f the eight positive clones was determined using the mAb-based rat 
g isotyping kit (BD Pharmingen). Among them, only three (E12, F8 
nd A1) recognized both recombinant human and mouse TP53INP1 
roduced in eucaryotic expression system (COS cells). E12 was shown 
o be the only mAb able to detect TP53INP1 by IHC. For Western blot- 
ing and IHC methods, see our previous publications taking advantage 
f those mAbs [ 11 –13 ]. These mAbs are regularly freely distributed to 
cademic or clinic researchers for their own research purposes (see 
eferences in Table 1 ). 2.1.2. Epitope mapping 
In order to determine which part of TP53INP1 is recognized by 
the three different mAbs, the sequences of human TP53INP1 α (164 
aa) and TP53INP1 β (240 aa) were divided into three and four regions, 
respectively. Regions 1 and 2 correspond to aa 2–42 and aa 33–110 
of both TP53INP α and β, respectively, region 3 corresponds to aa 
101–164 of TP53INP1 α (and includes aa 101–157 of TP53INP1 β), and 
region 4 corresponds to aa 152–240 of TP53INP1 β. These sequences 
were cloned into the procaryotic expression vector pQE-30 (Qiagen). 
Proteins lysates were blotted onto nitrocellulose membranes and hy- 
bridized with the different mAbs. 
2.1.3. MAbs puriﬁcation 
The hybridomas were gradually adapted in serum-free medium 
(SFM purchased from Invitrogen) and cultivated in CELLine devices 
(BD Biosciences) which allow production of mAb in a small volume 
(15 ml). The mAbs were puriﬁed onto Protein G-Sepharose (1 col- 
umn per mAb), and dialyzed in PBS. Concentration was determined 
by spectrometry at 280 nm (DO = 1 corresponds to 0.75 mg / ml of an- 
tibody), and purity was checked by SDS-PAGE followed by Coomassie 
blue staining. Puriﬁed mAbs were stored aliquoted at −20 ◦C after 
addition of 0.02% NaAzide. 
2.1.4. MAbs biotinylation 
The antibodies were biotinylated using the EZ-Link 
®
Micro NHS- 
PEG4-Biotinylation Kit (Thermo scientiﬁc) according to manufacturer 
instructions. Biotinylation was checked by Western blotting using 
streptavidin-HRP. 
2.2. TP53INP1 α and TP53INP1 β recombinant protein production 
TP53INP1 α and β recombinant proteins were produced in insect 
cells as described elsewhere [ 20 ]. Brieﬂy, the ampliﬁed cDNA frag- 
ments of the human TP53INP1 gene (aa 2–164 and aa 2–240 for full- 
length TP53INP1 α and TP53INP1 β, respectively) were subcloned into 
the BglII / AgeI site of the pMT / BiP / V5-His A plasmid (Invitrogen). This 
vector uses the Drosophila metallothionein MT gene promoter that is 
induced in Drosophila S2 cells upon addition of copper sulfate to the 
culture medium. The N-terminal signal sequence from the insect BiP 
gene directs the recombinant fusion protein through the secretory 
pathway of S2 cells into the culture medium. The recombinant pro- 
tein is tagged at the carboxy-terminal extremity by a 6xHis sequence 
(note that the V5 tag is removed upon cloning since its sequence is 
upstream the AgeI cloning site). The plasmids were co-transfected 
with the pAc5C-pac vector into Drosophila S2 cells according to man- 
ufacturer’s indications (Invitrogen). Stable clones were obtained us- 
ing puromycin selection. Cells were grown in suspension at 23 ◦C 
at a cell density of 3–4 × 10 6 cells / ml and kept under selection in 
Schneider’s medium (Sigma) containing 0.5 μg / ml puromycin (In- 
vitrogen), 50 μg / ml streptomycin (Gibco), and 10% heat-inactivated 
foetal bovine serum (Gibco). Expression of the secreted protein was 
induced by addition of 0.5 mM CuSO 4 . After 5 days, cells were asep- 
tically centrifuged, resuspended in fresh medium and induced again 
for 5 days (upto 10 inductions could be done using the same cells). 
The collected medium was centrifuged (4000 g for 5 min at 
4 ◦C), ﬁltered for clariﬁcation (through 0.45 μm ﬁlter), and the 
protein was puriﬁed by afﬁnity chromatography using Chelating 
Sepharose (GE Healthcare) equilibrated in 20 mM Na-phosphate pH 
7.4, 500 mM NaCl. TP53INP1 α and TP53INP1 βwere eluted with equi- 
libration buffer containing increasing concentrations of imidazole 
(10–500 mM). Fractions containing recombinant protein were deter- 
mined by Western blotting using F8 mAb, pooled, concentrated and 
buffer-exchanged into 20 mM Hepes pH 7.2 and 150 mM NaCl using a 
Millipore Ultrafree-15 spin concentrator. Protein concentration was 
monitored by spectrometry (280 nm absorbance). This procedure led 
to partial puriﬁcation of TP53INP1 α and β recombinant proteins that 
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Table 1. 
Expression of TP53INP1 in tumoral part of affected organ in cancer patients. 
Organ TP53INP1 status Mechanism a References 
Breast Protein decrease (IHC mAb E12) ND [ 21 ] 
Stomach Protein decrease or loss (IHC mAb E12) ND [ 22 ] 
Pancreas Protein loss (IHC mAb E12) Post-transcriptional regulation by 
miR-155 
[ 12 ] 
Liver Protein loss (IHC mAb E12) Post-transcriptional regulation by 
miR-130b 
[ 23 ] 
Colon Down-regulated (Q RT-PCR) Post-transcriptional regulation by 
miR-155 
[ 24 ] 
Œsophagus Down-regulated (Q RT-PCR) Promotor methylation [ 25 ] 
Thyroid High level in anaplastic carcinoma (IHC 
mAb E12) 
ND [ 26 ] 
Prostate De novo expression (IHC mAb E12) ND [ 17 , 18 ] 
This table recapitulates the state-in-the-art regarding TP53INP1 expression alterations in different cancers. Most of data, obtained by immunohistochemistry using the E12 mAb, 
are related to protein level. Some data related to mRNA level (obtained by quantitative RT-PCR) are also reported. The underlying mechanism of expression alteration is speciﬁed 
when elucidated. 
a ND = not determined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 we named “semi-puriﬁed” recombinant protein and used for ELISA
development. 
2.3. Development of the sandwich ELISA test to detect TP53INP1 
The ﬁrst step is a coating of 96-well microtitration plates (Nunc-
Sorb) with mAb (100 μl at 5 μg / ml in PBS, 4 ◦C ON). After four washes
with PBS, the wells are saturated with BSA (200 μl, 3% in PBS, at least
2 h at RT). After four washes with PBS, 100 μl of sample containing
TP53INP1 protein is deposited in the wells, and protein is allowed to
bind to its speciﬁc mAb during 3 h at RT. All proteins not speciﬁcally
bound are eliminated by four washes with PBS. Then the biotinylated
mAb is added (100 μl at 1 μg / ml in PBS, 45 min at RT). After four
washes with PBS, streptavidin-HRP (Beckman) is added (100 μl, 1 /
1000 in PBS, 1% BSA, 30 min at RT). After four washes with PBS, 100 μl
of HRP substrate (TMB: 3,3 ′ ,5,5 ′ -tetramethylbenzidine; Thermo Sci-
entiﬁc Pierce) are deposited and reaction is allowed during 15 min
in dark (upon oxidation, TMB forms a water-soluble blue reaction
product that can be measured spectrophotometrically at 650 nm).
Reaction is then stopped by addition of 100 μl H 2 SO 4 2 M (upon acid-
iﬁcation, the reaction product becomes yellow with an absorbance
peak at 450 nm). Absorbance at 450 nm (yellow) is monitored on a
plate-reader device. 
2.4. Cell culture 
HEK293T (Human Embryonic Kidney) and LNCaP (Human prostate
cancer) cell lines were purchased from the American Type Culture Col-
lection (Manassas, VA, USA), and maintained in DMEM Glutamax and
RPMI 1640 medium, respectively (Life Technologies, Inc., Gaithers-
burg, MD), supplemented with 10% (v / v) fetal bovine serum (FBS),
in a humidiﬁed atmosphere with 5% CO 2 at 37 
◦C. HEK293T cells
transiently transfected with TP53INP1 expression vectors were used
as control during ELISA development. For that purpose, human full-
length TP53INP1 αand βcDNAs containing a myc tag at the C-terminus
were subcloned into the pcDNA3.1 (Invitrogen), and constructions
were transfected into HEK293T cells using FuGENE HD (Promega)
according to manufacturer’s instructions. Cell lysates were obtained
48 h after DNA transfection, by resuspension of cells in lysis buffer
(50 mM Hepes, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol,
1% triton X-100, 25 mM NaF, 10 μM ZnCl 2 , 1 mM Na 3 VO 4 , protease
inhibitors cocktail (Sigma-Aldrich)). This same lysis buffer was used
to obtain LNCaP cell lysates. 2.5. PC patients and healthy donors 
Sera used in this study were from prostate cancer patients
prospectively recruited between January 2009 and January 2010. This
study was approved by the Institutional Ethic Committee Review
Board (Comit ´e d ’ Orientation Strat ´egique (COS), Marseille, France)
from the Institut Paoli-Calmettes (Marseille, France). During the in-
clusion visit, each patient gave written informed consent for research
use. Blood was sampled before or during the surgical diagnostic or
therapeutic act, serum was recovered and stored at −20 ◦C. We also
included a control group of healthy donors, recruited from the “Etab-
lissement Fran c ¸ ais du Sang” (EFS). 
3. Results and discussion 
3.1. Description of the ELISA procedure 
The ELISA principle is based on a sandwich immunoenzymatic
system (Scheme on Fig. 1 ). The ﬁrst step is a coating of microtitra-
tion plates with TP53INP1-speciﬁc antibodies. After saturation of free
plastic with BSA, sample containing TP53INP1 is deposited in the
wells and allowed to bind to its speciﬁc mAb (second step). All pro-
teins not speciﬁcally bound are eliminated by washing. Then anti-
TP53INP1 antibodies coupled to biotin are allowed to attach to the
bound TP53INP1 (third step). The fourth and last step is the detection
of antigen-antibody complexes by a streptavidin-peroxidase (HRP)
complex which is visualized by the addition of a chromogenic sub-
strate (TMB on the scheme). The intensity of the color reaction is pro-
portional to the quantity of TP53INP1 bound in the second step. Thus
development of this ELISA required monoclonal antibodies raised
against TP53INP1 as well as recombinant protein. 
3.2. Production of rat monoclonal antibodies speciﬁc of TP53INP1 
The generation of mAbs recognizing speciﬁcally TP53INP1 was
partly reported in previous publications [ 12 , 13 ]. We provide here the
entire description of the endeavor. 
Eight different mAbs speciﬁc for mouse and human TP53INP1 were
obtained, all of them recognizing recombinant TP53INP1 produced in
a bacterial expression system by Western blotting. Among them, only
three (E12, F8 and A1) recognized recombinant TP53INP1 produced
in a eucaryotic expression system by Western blotting. In addition,
E12 (also known as A25E12) was shown to be the only mAb working
in immunohistochemistry (IHC). Epitope mapping showed that both
mAbs E12 and F8 recognize an epitope located between aa 42 and 100,
whereas the epitope recognized by the mAb A1 is located between aa
101 and 151 ( Table 2 ). 
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Table 2. 
Speciﬁcities of the three rat monoclonal antibodies recognizing human and mouse TP53INP1 (both α and β isoforms) 
Name Isotype Epitope mapping Applications 
A1 IgG2a aa 111–151 Region ELISA 
WB recombinant protein 
E12 IgG2a aa 42–100 Region ELISA 
WB recombinant protein 
IHC (human samples) 
F8 IgG2a aa 42–100 Region ELISA 
WB recombinant and endogenous protein 
Fig. 1. Schematic model of the sandwich ELISA protocol. The ﬁve steps are: (1) coating 
of microplate wells with primary monoclonal antibody (mAb), (2) binding of TP53INP1 
α or β protein, (3) attachment of the secondary biotinylated mAb to TP53INP1, (4) 
detection of biotin by streptavidin-HRP, and ﬁnally (5) enzymatic activity monitored 
by addition of 3,3 ′ ,5,5 ′ -Tetramethylbenzidine (TMB) chromogenic substrate. 
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Fig. 2. Production and semi-puriﬁcation of TP53INP1 recombinant proteins in 
Drosophila cells. (A) Recombinant proteins expression was induced or not by addi- 
tion of CuSO 4 in culture media of insect Schneider 2 (S2) cells stably transfected with 
constructs encoding TP53INP1 α or β. Five days later, presence of TP53INP1 proteins 
in culture supernatants was veriﬁed by Western blotting thanks to anti-TP53INP1 F8 
(upper part) and E12 (bottom part of the ﬁgure) antibodies. NI: induced; I: induced. 
(B) Partial puriﬁcation of His-tagged TP53INP1 α recombinant protein produced in 
S2 inducible system was performed on a chelating column. After loading of culture 
supernatant, fractions were eluted via an imidazole gradient. Loading, ﬂow through, 
fractions and regenerated resin were analyzed by Western blotting using F8 mAb. 
Several batches of recombinant proteins were produced. Controls of expression and 
puriﬁcation were done for each batch. Representative blots are shown here. For the ELISA development, we cultivated the three hybridoma in 
erum-free medium in order to avoid the presence of immunoglobu- 
ins from calf serum. In addition, antibodies production was made in a 
D CELLine device, which allows high antibody concentrations within 
 small volume of medium, thus facilitating the step of mAb puriﬁca- 
ion on ProteinG. After puriﬁcation and quantiﬁcation at 280 nm, we 
hecked that puriﬁed mAbs recognized TP53INP1 by Western blotting 
n recombinant protein ( Fig. 2 A). 
.3. Production of recombinant protein 
Full-length human TP53INP1 α and β were cloned in pMT / BiP / 
5-His A vector for expression in Drosophila S2 cells. Owing to the 
resence of the BiP signal sequence, the 6xHis-tagged recombinant 
rotein is secreted into the culture medium. The ﬁrst ELISA trials 
see above) were made using crude culture medium of induced cells 
hown in Fig. 2 A. Then partial puriﬁcation of His-tagged recombinant 
roteins was performed on a chelating column eluted with an imida- 
ole gradient. The different fractions were tested by Western blotting 
sing the F8 mAb ( Fig. 2 B). Both TP53INP1 α and β are enriched in the 
50 mM imidazole fraction (we named this fraction “semi-puriﬁed”
ecombinant protein). 
.4. Development of the sandwich ELISA test to detect TP53INP1 α and 
We ﬁrst tested the six combinations: coated mAb (ﬁrst step of 
LISA procedure) and biotinylated mAb (third step) by using recom- 
inant TP53INP1 in crude culture medium of insect cells. Fig. 3 shows 
hat the best combinations are: coated E12 or F8 with biotinylated A1. Note that coated E12 + biotinylated A1 and coated A1 + biotiny- 
lated E12 do not generate the same absorbance reading, nor coated F8 
+ biotinylated A1 and coated A1 + biotinylated F8. To explain this 
initially unexpected result, we postulate that A1 is more efﬁcient in 
recognizing its TP53INP1 epitope when in solution than when coated. 
We subsequently performed ELISA experiments with either one 
of the two combinations: coated E12 or F8 with biotinylated A1. We 
also performed assays with coated E12 + F8 mix combined with 
biotinylated A1 for optimized detection of TP53INP1 (see below). 
We then assessed whether the ELISA signal is speciﬁc of TP53INP1 
by testing serial dilutions of semi-puriﬁed TP53INP1 α and β recom- 
binant protein samples. As shown in Fig. 4 , the signal is proportional 
to protein dilution, showing that the assay is speciﬁc for TP53INP1. 
The signal is linearly proportional to dilution in the case of TP53INP1 
β, whereas a saturating plateau is observed in the case of TP53INP1 α
probably because of higher concentration in the experimental sample. 
Afterwards, we conﬁrmed the speciﬁc detection of TP53INP1 us- 
ing two other sources of human TP53INP1 protein. TP53INP1-negative 
HEK293T cells were transfected with a vector encoding Myc-tagged 
TP53INP1 α, and lysates were tested in ELISA. TP53INP1 is detected in 
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Fig. 3. Test of different mAbs combinations for the ELISA. Different combinations of 
coated / biotinylated mAbs were tested for ELISA using A1, E12 or F8 antibodies and 
recombinant TP53INP1 α or β in crude culture medium of insect cells. Streptavidin–
HRP and TMB chromogenic substrate were then added to the well and optic density 
(OD) was read at 450 nm after stopping enzymatic reaction with H 2 SO 4 . This test was 
done twice with identical results. 
Fig. 4. ELISA curves obtained with serial dilution of TP53INP1 αand TP53INP1 β recom- 
binant samples. ELISA with (A) F8 or (B) E12 coated mAb were undertaken on serial 
dilutions of semi-puriﬁed TP53INP1 α or β recombinant protein (on the X axis, 1.0 
corresponds to undiluted sample). OD was then read at 450 nm. This experiment was 
done several times since systematically done for each recombinant protein production 
and during each ELISA experiment (standard curve). One representative experiment is 
shown here. 
 
 
 
 
Fig. 5. Detection of TP53INP1 in human cells lysates and in serum of prostate cancer pa- 
tients. (A) Detection of human Myc-tagged TP53INP1 α recombinant protein produced 
in transiently transfected HEK293T cells by ELISA with coated F8 mAb. Negative control 
corresponds to lysate of HEK293T cells transiently transfected with the empty vector. 
(B) Detection of endogenous TP53INP1 in human LNCaP cell line was assessed by ELISA 
with coated mAbs F8, E12 or F8 + E12 mix as speciﬁed. TP53INP1-negative HEK293T 
cell lysate was used as negative control. (C) Detection of endogenous TP53INP1 in serial 
dilutions of sera from prostate cancer patients was checked by ELISA with coated F8 
+ E12 mix mAbs. A TP53INP1-negative serum (from healthy donor) is also shown (H1, 
CTRL). Each of the experiments shown in this ﬁgure was done at least twice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 lysates of TP53INP1-transfected cells and not in lysates of cells trans-
fected with empty vector ( Fig. 5 A). In addition, TP53INP1 is success-
fully detected in lysates of cells that constitutively express TP53INP1,
i.e. the Prostate Cancer cells LNCaP ( Fig. 5 B). Interestingly, coated E12mAb is more powerful than F8 in detecting TP53INP1 in LNCaP lysate,
possibly owing to protein conformation. This observation motivated
the use of a mix of mAbs (F8 + E12) at the coating step of the ELISA. We
checked that this strategy is able to detect TP53INP1 in LNCaP lysate
( Fig. 5 B). Note that the peak of OD450 signal appeared at 1:4 dilutions
(0.25), suggesting that TP53INP1 is more efﬁciently detected when
partly diluted in LNCaP lysate because of other components (Triton
detergent in lysis buffer or cell components) that can hinder antigen-
antibody interaction. This is the reason why it is recommended to test
serial dilution whenever a sample is tested. 
Altogether, those results demonstrate that our sandwich ELISA
is successful in detecting both isoforms of TP53INP1 protein from
different sources. This is an indirect ELISA in which the protein is cap-
tured by two different antibodies, thus increasing the speciﬁcity of
the detection. Several commercial companies purchase rabbit poly-
clonal antibodies raised against a peptide, which are not as efﬁcient
and speciﬁc compared to our monoclonal antibodies, and which do
not permit an indirect ELISA. Upon request, we freely provide our
puriﬁed monoclonal antibodies to collaborators in the scientiﬁc com-
munity according to application ( Table 2 ). 
3.5. Relevance of the sandwich ELISA test to detect TP53INP1 in human 
serum 
To address the ability of this ELISA to detect TP53INP1 in human
serum, we tested sera from 38 prostate cancer (PC) patients. Eight
56 Houda Saadi et al. / Results in Immunology 3 (2013) 51–56 
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Rera were found positive, i.e. gave an absorbance at least two-fold the 
bsorbance monitored with PBS in ELISA assay with coated F8 mAb, 
wo of which were also positive with coated E12 mAb (correspond- 
ng to the two ones given the highest absorbance with coated F8). 
s discussed for LNCaP lysate, this difference of sensitivity between 
oated E12 and F8 stands possibly from different conformational state 
f TP53INP1 protein depending on the context. We then performed 
LISA using a mix of F8 and E12 mAbs for the coating step. Fig. 5 C 
hows curves obtained with serial dilutions of three out of the eight 
ositive sera. Altogether those data demonstrate that the TP53INP1 
LISA is potent in detecting TP53INP1 protein in human serum. It will 
e crucial to analyse the association between positive TP53INP1 in the 
LISA and clinical state of the patients. We are currently recruiting a 
ubstantial cohort of PC patients, which we will test in a near future, 
o obtain statistically relevant data comparing TP53INP1 presence in 
erum and clinical outcome. In addition, these data highlight the ad- 
antage of using a mix of coated mAbs in order to ﬁsh all TP53INP1 
roteins independently of conformational state or isoform. 
. Conclusion 
In summary we here developed and validated a standardized ELISA 
or the detection of TP53INP1 in human serum. This new assay will 
ow allow addressing the question of whether TP53INP1 could be a 
iomarker for prostate cancer or other cancers, by reliable detection 
f TP53INP1 in serum of large patient cohorts. Efforts in that direction 
re ongoing in the laboratory. In addition, sensitivity of this assay will 
e determined by using pure recombinant proteins, which requires 
urther steps of puriﬁcation. 
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